Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
6.17
-0.08 (-1.28%)
Nov 20, 2024, 4:00 PM EST - Market closed
Adverum Biotechnologies Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ADVM stock have an average target of 27.83, with a low estimate of 10 and a high estimate of 40. The average target predicts an increase of 351.05% from the current stock price of 6.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADVM stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +386.22% | Nov 19, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $12 → $10 | Hold | Maintains | $12 → $10 | +62.07% | Nov 5, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $60 → $40 | Strong Buy | Maintains | $60 → $40 | +548.30% | Aug 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +386.22% | Aug 13, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $15 → $12 | Hold | Maintains | $15 → $12 | +94.49% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
637.50K
from 3.60M
Decreased by -82.29%
Revenue Next Year
8.89M
from 637.50K
Increased by 1,294.35%
EPS This Year
-5.17
from -11.62
EPS Next Year
-5.05
from -5.17
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.1M | 63.0M | 63.0M | ||
| Avg | 637,500 | 8.9M | 20.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -70.8% | 9,782.4% | 608.7% | ||
| Avg | -82.3% | 1,294.4% | 133.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.85 | -2.77 | -2.46 | ||
| Avg | -5.17 | -5.05 | -4.61 | ||
| Low | -5.84 | -6.08 | -6.42 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.